Current Drug Targets

Francis J. Castellino
Kleiderer-Pezold Professor of Biochemistry
Director, W.M. Keck Center for Transgene Research
Dean Emeritus, College of Science
230 Raclin-Carmichael Hall, University of Notre Dame
Notre Dame, IN 46556


Catecholaminergic Strategies for the Treatment of Major Depression

Author(s): Philippe Tremblay and Pierre Blier

Affiliation: Institute of Mental HealthResearch, Lady Grey Building, suite 2043, Royal Ottawa Hospital, Universityof Ottawa, Ottawa, Canada.


Although the selective serotonin reuptake inhibitors have become the first line medications for the treatment of depression, drugs primarily targeting the norepinephrine (NE) and/or the dopamine catecholaminergic systems are also effective. These include selective NE reuptake inhibitors, such as desipramine and reboxetine, the NE releaser bupropion and the α2-adrenergic antagonists mianserin and mirtazapine. Dopamine type 2 agonists are also effective in treating depression, although they are rarely used. Since the NE, dopamine and serotonin systems have reciprocal interactions, it is virtually impossible to act on a specific neuronal element without affecting in a cascade effect the two other systems. In this review, the primary actions of the catecholaminergic strategies upon their acute and long-term administration are described, as well as their impact on other systems. Their use in treatment-resistant depressed patients is also addressed.

Keywords: Dopamine, norepinephrine, serotonin, locus coeruleus, raphe nuclei, ventral tegmental area

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [149 - 158]
Pages: 10
DOI: 10.2174/138945006775515464
Price: $58